does tirzepatide cause bone density loss Tirzepatide, a dual GLP-1 and GIP receptor agonist, promotes in obese mice via gut microbial-related metabolites Tirzepatide, a dual GLP-1 and

Task force members report early experience across three distinct cases of locally advanced CRC in patients with severe obesity, demonstrating successful preoperative visceral fat reduction through multidisciplinary coordination incorporating metabolic bariatric surgery or pharmacologic therapy during neoadjuvant windows, followed by definitive oncologic resection

GLP-1 side effects like dry mouth and acid reflux may be behind Ozempic teeth. Heres the science of how these drugs impact oral health.

Read an editorial review of AgelessRx: GLP-1 medication options, pricing tiers, compounded-pharmacy pathway, and program structure

instead, it raises blood pressure and reduces the effectiveness of ant...

doi:10.3390/ijms24021703 Contributor A